financetom
Business
financetom
/
Business
/
Sabre Strikes $1.1 Billion Deal to Sell Hospitality Solutions Business to TPG; Sabre's Stock Jumps
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sabre Strikes $1.1 Billion Deal to Sell Hospitality Solutions Business to TPG; Sabre's Stock Jumps
May 25, 2025 8:11 PM

11:48 AM EDT, 04/28/2025 (MT Newswires) -- Sabre (SABR) agreed to sell its hospitality solutions business to alternative asset management firm TPG (TPG) for $1.1 billion in cash.

The transaction, which requires approval from regulators, is expected to complete by the end of the third quarter of this year, the companies said Monday in a joint statement. The hospitality solutions segment supports the central reservation platform of more than 40% of the world's leading hotel brands.

Sabre, which is a technology provider to the travel industry, expects net proceeds of roughly $960 million from the deal. That money will be used to pay down debt and "optimize focus on its core business," the company said.

Sabre's stock were advancing by about 18% in Monday trade, while TPG shares were down 0.3%.

"This divestiture positions Sabre to focus on our core airline IT and travel marketplace platforms," Chief Executive Kurt Ekert said. "We are confident that TPG's investment approach and expertise will drive significant value to all of Hospitality Solutions' customers."

Sabre's hospitality solutions revenue grew 7% year over year to $326.8 million in 2024.

As part of the deal with TPG, Sabre agreed to provide certain services to support the transition of the hospitality solutions business.

"The hospitality industry continues to evolve rapidly. Hospitality Solutions' tailored offering is enabling hotels of all types to meet guests where they are and truly prioritize their needs," TPG Partner Paul Hackwell said. "The transaction brings together our decades of investing experience across the travel and software sectors, and we look forward to working with the team to build the platform into a comprehensive technology provider for the hospitality industry."

Price: 2.59, Change: +0.40, Percent Change: +18.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Stellantis to Offer At-Home Charging Station or Charge Credits With EV Purchase
Stellantis to Offer At-Home Charging Station or Charge Credits With EV Purchase
Jul 15, 2024
12:50 PM EDT, 07/15/2024 (MT Newswires) -- Stellantis ( STLA ) said Monday it would begin offering customers at-home charging stations or charge credits with the purchase of battery electric vehicles. The company announced the offerings under a program called Free2move Charge which would either offer customers a level 2 charging unit at their home or $600 in charging credits...
US judge sets quick schedule to consider family objections to Boeing plea deal
US judge sets quick schedule to consider family objections to Boeing plea deal
Jul 15, 2024
WASHINGTON (Reuters) - A U.S. judge on Monday set a fast schedule to consider the objections of relatives of those killed in two fatal 737 MAX crashes to the Justice Department's plea deal with Boeing ( BA ). The planemaker on July 7 agreed in principle to plead guilty to a criminal fraud conspiracy charge and pay a fine of...
Why Mira Pharmaceuticals Stock Is Moving Higher Monday
Why Mira Pharmaceuticals Stock Is Moving Higher Monday
Jul 15, 2024
MIRA Pharmaceuticals, Inc. ( MIRA ) shares are trading higher after the company said testing has confirmed its preliminary beliefs regarding a new potential treatment for neurological and neuropsychiatric disorders. The Details: The company is currently evaluating a pharmaceutical drug, MIRA-55, as a possible treatment for anxiety and cognitive decline. Preclinical tests showed promising results including stronger efficacy when compared...
Update: Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder
Update: Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder
Jul 15, 2024
12:50 PM EDT, 07/15/2024 (MT Newswires) -- (Updated with share price movement in the headline and first paragraph) Lexeo Therapeutics ( LXEO ) shares sank more than 29% in recent Monday trading despite positive interim data from phase 1/2 trials of its experimental gene therapy, LX2006, to treat Friedreich ataxia cardiomyopathy. Earlier in the day, the company said the trial...
Copyright 2023-2026 - www.financetom.com All Rights Reserved